Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.
Song H, Li H, Guo S, Pan Y, Fu Y, Zhou Z, Li Z, Wen X, Sun X, He B, Gu H, Zhao Q, Wang C, An P, Luo S, Hu Y, Xie X, Lu B.
Song H, et al. Among authors: he b.
Brain. 2018 Jun 1;141(6):1782-1798. doi: 10.1093/brain/awy081.
Brain. 2018.
PMID: 29608652
Free PMC article.